Paclitaxel in anthracycline-treated breast cancer patients

Oncology Reports

Volumn 5, Issue 4, 1998, Pages 915-918

  Pugliese, Palma ^a   Brugnatelli, S ^a   Giordano, M ^b   Danova, M ^a   De Monte, A ^c   Richetti, A ^d   Fava, S ^e   Rinaldi, E ^f   Fregoni, V ^g   Epifani, C ^b   Riccardi, A ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b SANT ANNA HOSPITAL   (Italy)

^c Ospedale Civile Predabissi   (Italy)

^d OSPEDALE DI CIRCOLO   (Italy)

^e Ospedale di Legnano   (Italy)

^f Ospedale di Magenta   (Italy)

^g Ospedale di Lodi   (Italy)

Author keywords

Anthracycline; Metastatic breast cancer; Paclitaxel

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; PACLITAXEL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 13144305032     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.4.915     Document Type: Article

References (29)

1. Riccardi A, Brugnatelli S, Giordano, et al: Advanced breast cancer: a randomized study of different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-fluorouracil. Oncol Rep 2: 577-582, 1995.
2. Henderson IC, Hayes DF and Gelman R: Dose response in the treatment of breast cancer: a critical review. J Clin Oncol 6: 1501-1515, 1988.
3. Wheeler RH, Ensminger WD, Thrall JH, et al: High-dose doxorubicin: an exploration of the dose response curve in human neoplasia. Cancer Treat Rep 66: 493-498, 1992.
4. Hortobagy GN, Bodey GB, Buzdar AU, et al: Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol 5: 354-364, 1987.
5. Carmo-Pereira J, Oliveira-Costa F, Henriques E, et al: A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast cancer. Br J Cancer 56: 417-473, 1987.
6. Habeshaw T, Paul J, Jones R, et al: Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial. J Clin Oncol 9: 295-304, 1991.
7. French Epirubicin Study Group: A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol 9: 305-312, 1991.
8. Focan C, Andrien JM, Closon MT, et al: Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial. J Clin Oncol 11: 1253-1263, 1993.
9. Marschner N, Kreienberg R, Souchon R, et al: Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: interim analysis of a prospective randomized trial. Semin Oncol 21: 10-16, 1994.
10. Rowinsky EK, Cazenave LA and Donehower RC: Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247-1259, 1990.
11. Eisenhauer EA, ten Bokkel Huinink W, Swenerton KD, et al: European-Canadian randomized trial of Paclitaxel in relapsed ovarian cancer: High versus low dose and long versus short infusion. J Clin Oncol 12: 2654-2666, 1994.
12. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Paclitaxel, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991.
13. Gianni L, Kerns CM, Gianni A, et al: Non-linear pharmacokinetics and metabolism of Paclitaxel and its pharmacokinetic/ pharmacodynamics relationships in humans. J Clin Oncol 13: 180-190, 1995.
14. Nabholtz JM, Gelmon K, Bontebal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14: 1858-1867, 1996.
15. Reichman BS, Seidman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11: 1943-1951, 1993.
16. Davidson NG, Chick JB, Perren TJ, et al: A phase II study of single agent Paclitaxel in patients at first relapse following initial chemotherapy for breast cancer. Clin Oncol 8: 358-362, 1996.
17. Sledge GW Jr, Robert N, Sparano JA, et al: Paclitaxel (Taxol) and doxorubicin combination in advanced breast cancer: The European Cooperative Oncology Group experience. Semin Oncol 21 (Suppl 8): 12, 1994.
18. Dombernowsky P, Gehl J, Boesgaard M, et al: Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol 23 (Suppl 1): 13-18, 1996.
19. Seidman AD, Reichman BS, Crown JPA, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 13: 1152-1159, 1995.
20. Wilson WH, Berg S, Bryant G, et al: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hours infusion. J Clin Oncol 12: 1621-1629, 1994.
21. A'Hern RP, Smith IE and Ebbs SR: Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67: 801-805, 1993.
22. Hortobagy G and Holmer S: Single agent paclitaxel for the treatment of breast cancer an overview. Semin Oncol 23 (Suppl 2): 46, 1996.
23. Conte PF, Michelotti A, Baldini E, et al: Activity and safety of epirubicin plus paclitaxel in advanced breast cancer. Semin Oncol 23 (Suppl 1): 33-36, 1996.
24. Fountzilas G, Athanassiades A, Giannakakis T, et al: A phase II study of Paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer 32(A): 47-51, 1996.
25. Seidman AD, Hudis CA, Raptis G, et al: Paclitaxel for breast cancer: The Memorial Sloan-Kettering Cancer Center Experience. Oncology 11 (Suppl 2): 20-28, 1995.
26. Gianni L, Munzone E, Capri G, et al: Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87: 1169-1175, 1995.
27. Vici P, Di Lauro L, Conti F, et al: Paclitaxel activity in anthracycline refractory breast cancer patients. Tumori 83: 661-664, 1997.
28. Roy SN and Horwith SB: A phosphoglycoprotein associated with Paclitaxel resistence in J774.2 cells. Cancer Res 45: 3856-3863, 1995.
29. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hours infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-fiding and sequence-finding study. J Clin Oncol 13: 2688-2699, 1995.